This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yau, C. Y.F. Articles by Hedley, D. W. Search for Related Content PubMed PubMed Citation Articles by Yau, C. Y.F. Articles by Hedley, D. W.

Inhibition of Integrin-Linked Kinase by a Selective Small Molecule Inhibitor, QLT0254, Inhibits the PI3K/PKB/mTOR, Stat3, and FKHR Pathways and Tumor Growth, and Enhances Gemcitabine-Induced Apoptosis in Human Orthotopic Primary Pancreatic Cancer Xenografts

¹ Division of Experimental Therapeutics, ² Department of Medical Oncology and Hematology, Ontario Cancer Institute/Princess Margaret Hospital, and ³ Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; and ⁴ Kinetek Pharmaceuticals, Inc., Vancouver, British Columbia, Canada

Requests for reprints: David W. Hedley, Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue Toronto, Ontario, Canada M5G 2M9. Phone: 416-946-2911; Fax: 416-946-6546; E-mail: david.hedley{at}uhn.on.ca.

Integrin-linked kinase (ILK) couples integrins and growth factors to downstream signaling pathways involving phosphatidylinositol 3-kinase, protein kinase B/Akt (PKB/Akt), and glycogen synthase kinase-3ß. The anticancer effects of ILK inhibitor QLT0254 were tested in an orthotopic primary xenograft model of pancreatic cancer. The pharmacodynamic effects of a single dose of QLT0254 on the phosphorylation of PKB/Akt were measured by immunohistochemistry and Western blotting, and showed a decrease of >80% after 2 hours, followed by recovery over 24 hours, consistent with the pharmacokinetic profile of this compound in mice. There was also suppression in phosphorylated PKB Thr³⁰⁸, forkhead in rhabdomyosarcoma, S6K1, S6, 4E-BP1, and signal transducers and activators of transcription 3 Tyr⁷⁰⁵ and Ser⁷²⁷ protein levels with ILK inhibition by QLT0254. However, we did not observe an effect on phosphoinositide-dependent kinase 1, glycogen synthase kinase-3ß, and extracellular signal-regulated kinase phosphorylation or on total PKB and ILK protein expression levels with QLT0254 treatment. In tumor growth inhibition experiments, daily treatment with QLT0254 for 3 weeks was well tolerated and produced significant tumor growth inhibition compared with vehicle control (P = 0.001). When a single dose of QLT0254 and chemotherapy agent gemcitabine was administered, there was a significant 5.4-fold increase in acute apoptosis in the combination therapy group compared with vehicle controls (P = 0.002). However, the acute effects of QLT0254 on proliferation were not statistically significant. These results show in vivo evidence that ILK plays a prominent role in oncogenic phosphatidylinositol 3-kinase/PKB signaling in vivo with major impact on the mammalian target of rapamycin, signal transducers and activators of transcription 3, and forkhead in rhadomyosarcoma signaling pathways, suggesting that ILK inhibitors might show activity in pancreatic cancer patients.

Key Words: protein kinase B • Akt • mammalian target of rapamycin • signal transducers and activators of transcription-3 • forkhead transcription factors

This article has been cited by other articles:

				P. C. McDonald, A. B. Fielding, and S. Dedhar Integrin-linked kinase - essential roles in physiology and cancer biology J. Cell Sci., October 1, 2008; 121(19): 3121 - 3132. [Abstract] [Full Text] [PDF]

				B. C. Fuchs, T. Fujii, J. D. Dorfman, J. M. Goodwin, A. X. Zhu, M. Lanuti, and K. K. Tanabe Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells Cancer Res., April 1, 2008; 68(7): 2391 - 2399. [Abstract] [Full Text] [PDF]

				P. C. McDonald, A. Oloumi, J. Mills, I. Dobreva, M. Maidan, V. Gray, E. D. Wederell, M. B. Bally, L. J. Foster, and S. Dedhar Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylation and Cancer Cell Survival Cancer Res., March 15, 2008; 68(6): 1618 - 1624. [Abstract] [Full Text] [PDF]

				S. B. Watzka, U. Setinek, M. Huber, H. Cantonati, F. Lax, S. Watson, G. Weigel, and M. R. Muller Reactivity of integrin-linked kinase in human mesothelial cell proliferation Interactive CardioVascular and Thoracic Surgery, February 1, 2008; 7(1): 107 - 110. [Abstract] [Full Text] [PDF]

				L. A. Edwards, J. Woo, L. A. Huxham, M. Verreault, W. H. Dragowska, G. Chiu, A. Rajput, A. H. Kyle, J. Kalra, D. Yapp, et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK) Mol. Cancer Ther., January 1, 2008; 7(1): 59 - 70. [Abstract] [Full Text] [PDF]

				V. A. Potiron, G. Sharma, P. Nasarre, J. A. Clarhaut, H. G. Augustin, R. M. Gemmill, J. Roche, and H. A. Drabkin Semaphorin SEMA3F Affects Multiple Signaling Pathways in Lung Cancer Cells Cancer Res., September 15, 2007; 67(18): 8708 - 8715. [Abstract] [Full Text] [PDF]

				C.-H. Tang, D.-Y. Lu, T.-W. Tan, W.-M. Fu, and R.-S. Yang Ultrasound Induces Hypoxia-inducible Factor-1 Activation and Inducible Nitric-oxide Synthase Expression through the Integrin/Integrin-linked Kinase/Akt/Mammalian Target of Rapamycin Pathway in Osteoblasts J. Biol. Chem., August 31, 2007; 282(35): 25406 - 25415. [Abstract] [Full Text] [PDF]

				M. Satpathy, L. Cao, R. Pincheira, R. Emerson, R. Bigsby, H. Nakshatri, and D. Matei Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase Cancer Res., August 1, 2007; 67(15): 7194 - 7202. [Abstract] [Full Text] [PDF]

				R. P.C. Wong, P. Ng, S. Dedhar, and G. Li The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth Mol. Cancer Ther., June 1, 2007; 6(6): 1692 - 1700. [Abstract] [Full Text] [PDF]

				J. V. Spencer The Cytomegalovirus Homolog of Interleukin-10 Requires Phosphatidylinositol 3-Kinase Activity for Inhibition of Cytokine Synthesis in Monocytes J. Virol., February 15, 2007; 81(4): 2083 - 2086. [Abstract] [Full Text] [PDF]

				Y. Tabe, L. Jin, Y. Tsutsumi-Ishii, Y. Xu, T. McQueen, W. Priebe, G. B. Mills, A. Ohsaka, I. Nagaoka, M. Andreeff, et al. Activation of Integrin-Linked Kinase Is a Critical Prosurvival Pathway Induced in Leukemic Cells by Bone Marrow-Derived Stromal Cells Cancer Res., January 15, 2007; 67(2): 684 - 694. [Abstract] [Full Text] [PDF]

				S. Naska, K. J. Park, G. E. Hannigan, S. Dedhar, F. D. Miller, and D. R. Kaplan An Essential Role for the Integrin-Linked Kinase-Glycogen Synthase Kinase-3{beta} Pathway during Dendrite Initiation and Growth J. Neurosci., December 20, 2006; 26(51): 13344 - 13356. [Abstract] [Full Text] [PDF]

				H. Lu, P. W. M. Fedak, X. Dai, C. Du, Y.-Q. Zhou, M. Henkelman, P. S. Mongroo, A. Lau, H. Yamabi, A. Hinek, et al. Integrin-Linked Kinase Expression Is Elevated in Human Cardiac Hypertrophy and Induces Hypertrophy in Transgenic Mice Circulation, November 21, 2006; 114(21): 2271 - 2279. [Abstract] [Full Text] [PDF]

				K. E. Krueger and S. Srivastava Posttranslational Protein Modifications: Current Implications for Cancer Detection, Prevention, and Therapeutics Mol. Cell. Proteomics, October 1, 2006; 5(10): 1799 - 1810. [Full Text] [PDF]

				A. A. Troussard, P. C. McDonald, E. D. Wederell, N. M. Mawji, N. R. Filipenko, K. A. Gelmon, J. E. Kucab, S. E. Dunn, J. T. Emerman, M. B. Bally, et al. Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival Cancer Res., January 1, 2006; 66(1): 393 - 403. [Abstract] [Full Text] [PDF]

				M. Saleem, S. Kaur, M.-H. Kweon, V. M. Adhami, F. Afaq, and H. Mukhtar Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway Carcinogenesis, November 1, 2005; 26(11): 1956 - 1964. [Abstract] [Full Text] [PDF]

				M. N. Younes, S. Kim, O. G. Yigitbasi, M. Mandal, S. A. Jasser, Y. Dakak Yazici, B. A. Schiff, A. El-Naggar, B. N. Bekele, G. B. Mills, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer Mol. Cancer Ther., August 1, 2005; 4(8): 1146 - 1156. [Abstract] [Full Text] [PDF]